Additional Effects of Faricimab in Aflibercept Low-Responders: Retinal Morphology and Function in Eyes with Neovascular Age Related Macular Degeneration Following a Switch Between Two Anti-VEGF Agents
An initial loading dose could be beneficial to elongate Faricimab's additional effect of reducing retinal swelling in eyes with nAMD and previous low-response to Aflibercept. Serous and drusenoid PEDs seem to benefit more than fibrovascular PEDs. A high amount of intraretinal HRF in patients with PED was a sign for good respondence to Faricimab.
Authors
- Haidar Khalil (ORCID: https://orcid.org/0000-0002-0369-5237)
- Jan Rothbächer
- Matthias Bolz (ORCID: https://orcid.org/0000-0001-8691-5276)
- Markus Eidherr
Institutions
- Johannes Kepler University of Linz (AT)
- Kepler Universitätsklinikum (AT)
Publication Details
- Journal
- Clinical ophthalmology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.2147/opth.s530355
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00